Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 8Neuroectodermal Tumors, Primitive, Peripheral 4Wilms Tumor 3Malignant mesenchymal tumor 3Kidney Neoplasms 3Rhabdomyosarcoma 2Liposarcoma 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Fibrosarcoma 2Desmoplastic Small Round Cell Tumor 2Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Ovarian Neoplasms 1Neoplasms 1Chondrosarcoma 1

Interventions

temsirolimus 1ganitumab 1efineptakin alfa 1Vinorelbine 1Vincristine 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Radiotherapy 1Radiation 1Irinotecan 1Dasatinib 1Dactinomycin 1Cyclophosphamide 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rhabdomyosarcoma, Alveolar × Dactinomycin × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡